> 21_cfr_part_820_/_fda_qmsr
21 CFR Part 820 / FDA QMSR
FDA Quality Management System Regulation (QMSR)
FDA Quality Management System Regulation (QMSR) amends 21 CFR Part 820 by directly incorporating by reference the requirements of ISO 13485:2016 while retaining specific FDA statutory authorities. Effective February 2, 2026, QMSR eliminates unnecessary dual-compliance friction, harmonizes global audit expectations, and emphasizes risk management and design controls across regulated software and device lifecycles.
Scope & Applicability
Mandatory for all manufacturers, labelers, and packagers of finished medical devices distributed in the United States, including Software as a Medical Device (SaMD).
Non-Coverage Boundaries
Does not supersede FDA investigational device exemptions (IDE) or premarket authorization pathways (510(k), PMA, De Novo).
Key Clauses & Control Requirements
Incorporation of ISO 13485:2016
Substitutes legacy Quality System Regulation (QSR) requirements with direct reliance on ISO 13485:2016 clauses.
Required Regulatory & Audit Evidence Artifacts
- [✓]ISO 13485-aligned Quality Manual updated for QMSR terminology
- [✓]Design Controls traceability matrix matching FDA premarket submissions
- [✓]Documented Software Validation protocols and execution logs
“QMSR ends the legacy debate between 'doing FDA QSR' versus 'doing ISO 13485'. Regulated SaaS teams can now standardize on a single modern quality framework across US and global markets.”
Cross-Surface Ecosystem Relationships
- FDA Quality Management System Regulation Final Rule ↗(U.S. Food and Drug Administration)
Frequently Asked Questions
When did FDA QMSR take full effect?
FDA QMSR became effective on February 2, 2026, marking the formal retirement of the legacy 1996 QSR framework in favor of ISO 13485 alignment.